Signal Breakdown
6 verified publisher articles from recent coverage.
Limited TV coverage this week.
Limited video coverage this week.
GDELT tone + context across verified sources.
What’s Driving Sentiment
Bullish Signals
- Insulet completed a full U.S. rollout of Omnipod Discover, expanding access to all Omnipod 5 users.
- Early limited release saw adoption by over 15,000 users and more than 1,800 clinicians.
- Real-world engagement tied to the platform showed clinically meaningful time-in-range gains for about one-third of users.
- Shares rose 3.35% in one day and 5.95% over 30 days following the product expansion news.
Risk Factors
- Bronstein, Gewirtz & Grossman opened an investigation into Insulet, introducing potential legal and reputational risk.
- Insulet has a year-to-date share decline of 50.58%, reflecting significant recent investor skepticism.
- A small insider sale by Rep. Gilbert Cisneros was disclosed, though it was described as unlikely to affect fundamentals.
Evidence
- 2026-10-24Source: TIINGO
Summary: Insulet completed full U.S. rollout of Omnipod Discover, a web platform delivering weekly insulin and glucose insights to Omnipod 5 users, following limited release adoption by >15,000 users and 1,800 clinicians and international availability; early data show improved time-in-range.
Bullish - 2026-10-20Source: TIINGO
Summary: Insulet moved Omnipod Discover to a full U.S. launch, deploying its data platform to Omnipod 5 users and care teams; smartphone reports tied to real-world glycemic data showed engagement linked to clinically meaningful time-in-range gains for about one-third of users.
Bullish - 2026-10-17Source: TIINGO
Summary: Insulet launched full U.S. release of Omnipod Discover, a web-based data platform for Omnipod 5 that offers shared visual insights and personalized weekly reports; company reports time-in-range improvements and >15,000 users and >1,800 clinicians pre-rollout.
Bullish - 2026-10-14Source: TIINGO
Summary: Rep. Gilbert Cisneros sold $1,001–$15,000 of Insulet (NASDAQ:PODD) stock on Sept. 18, disclosed Oct. 12, via the '150 MAIN STREET TRUST > BANK OF AMERICA' account. The small trade is unlikely to materially affect Insulet's fundamentals or share price.
Neutral - 2026-10-13Source: TIINGO
Summary: Insulet moved Omnipod Discover from a limited rollout to a full U.S. release, making its web-based diabetes data platform available to all Omnipod 5 users. Shares rose 3.35% in one day and 5.95% over 30 days, despite a YTD decline of 50.58% and a 1-year TSR down 55.55%. The nationwide launch is a positive commercial catalyst that may improve adoption and sentiment.
Bullish - 2026-10-22Source: GDELT
Summary: Bronstein, Gewirtz & Grossman on Oct 22, 2026 announced an investigation into Insulet Corporation, indicating potential shareholder or securities claims; this represents a legal risk that could be negative for PODD's stock and reputation.
Bearish
Showing 6 of 6 verified news articles
- No current evidence is available for this source.
No current verified Archive TV segments
- No current evidence is available for this source.
No verified video evidence in the current 7-day window
Formula & Methodology
- News
- GDELT discovers coverage; only publisher passages that directly name the company qualify as news evidence.
- TV
- Internet Archive TV captions are retained only with a match-centered quote that directly names the company.
- Video
- Recent Bullish Gator videos tagged to the company; the item summary and publisher label feed the judge.
- Holistic AI judge
- A single Azure OpenAI call reads the news, television, and video evidence together and returns the rating, a 0–100 composite, and a short rationale. Thresholds are enum-only: 65+ Bullish, 35 or lower Bearish, Neutral in between.
Data Source
News evidence comes from the GDELT Global Knowledge Graph (via BigQuery); TV evidence from the Internet Archive TV News Archive; video evidence from recent Bullish Gator video coverage. Azure OpenAI filters per-article relevance and serves as the holistic AI judge that produces the composite rating. Portions use data from The GDELT Project under open data terms. This page is informational analysis, not investment advice. See Financial Disclaimer.